Remdesivir may lower risk of in hospital death among COVID-19 patients not requiring oxygen: Study

Remdesivir may lower the risk of in-hospital death among COVID-19 patients not requiring oxygen suggests a new study published in the Open Forum Infectious Diseases.

Use of Remdesivir was linked to a significant decline in in-hospital death at both 14 and 28 days, regardless of variant of concern. Remdesivir has demonstrated benefit in some hospitalized patients with COVID-19 on supplemental oxygen and in non-hospitalized patients at room air. The durability of this benefit across time periods with different circulating SARS-CoV-2 variants of concern (VOC) is unknown. This comparative effectiveness study compares inpatient mortality among patients hospitalized for COVID-19 not receiving supplemental oxygen at admission initiating remdesivir treatment in the first two days of admission vs. no remdesivir during the hospitalization across different VOC periods. Using a large, multicenter US hospital database, in-hospital mortality was compared among patients hospitalized for COVID-19 not requiring supplemental oxygen at admission between December 2020 and April 2022. Patients receiving remdesivir upon hospital admission were matched 1:1 to those not receiving remdesivir during hospitalization using propensity score matching. Cox proportional hazards models were used to assess 14- and 28-day in-hospital mortality or discharge to hospice. Results: Among the 121,336 eligible patients, 58,188 remdesivir-treated patients were matched to 17,574 unique non-remdesivir patients. Overall, 5.4% of remdesivir-treated and 7.3% of non-remdesivir patients died within 14 days, while 8.0% of remdesivir-treated and 9.8% of non-remdesivir patients died within 28 days. Remdesivir treatment was associated with a statistically significant reduction in in-hospital mortality compared to non-remdesivir treatment (14-day adjusted hazard ratio (aHR): 0.75, 95% confidence interval (CI): 0.68-0.83; 28-day aHR: 0.83, 0.76-0.90). This significant mortality benefit endured across the different VOC periods. Remdesivir initiation in patients hospitalized for COVID-19, not requiring supplemental oxygen at admission, was associated with a statistically significant reduction in in-hospital mortality. These findings highlight a potential survival benefit when clinicians initiated remdesivir upon admission across the dominant variant eras of the evolving pandemic.

Reference:

Essy Mozaffari, Aastha Chandak, Chidinma Chima-Melton, Andre C Kalil, Heng Jiang, EunYoung Lee, Celine Der-Torossian, Mark Thrun, Mark Berry, Richard Haubrich, Robert L Gottlieb, Remdesivir is associated with reduced mortality in patients hospitalized for COVID-19 not requiring supplemental oxygen, Open Forum Infectious Diseases, 2024;, ofae202, https://doi.org/10.1093/ofid/ofae202

Keywords:

Remdesivir, lower risk, hospital, death, among, COVID-19 patients, oxygen, study, Open Forum Infectious Diseases, Essy Mozaffari, Aastha Chandak, Chidinma Chima-Melton, Andre C Kalil, Heng Jiang, EunYoung Lee, Celine Der-Torossian, Mark Thrun, Mark Berry, Richard Haubrich, Robert L Gottlieb, COVID-19, comparative effectiveness research, hospitalization, mortality, remdesivir



from Medical News, Health News Latest, Medical News Today - Medical Dialogues | https://ift.tt/FZNRzt5

Comments

Post a Comment

Popular posts from this blog

'Details sought include Third-party info, hence exempted under RTI Act': NMC on RTI query on Faculty Gap in Medical Colleges

Image
New Delhi:  Stating that the details sought under the RTI includes third-party information, the National Medical Commission (NMC) has refused to disclose the names of the medical colleges that fell short on faculty counts and other teaching infrastructure. Recently activist Dr. KV Babu filed an application under the Right to Information Act seeking the details of the notices issued by the NMC Undergraduate Medical Education Board (UGMEB) to the medical colleges for deficiencies in Clinical Material and staff during the period from 01/01/2023 to 30/04/2024. He also sought to know the details of the fine imposed or the action taken by the NMC UG Board from 01/01/2023 to 30/04/2024. In response, the Apex medical regulatory body in India has said that the concerned information includes third party information. "Since the information sought by you, includes third party information, hence the same is exempted for as per Section 8(1) (j) of the Right to Information Act, 2005," th...
Read more

Intas Pharmaceuticals Gets CDSCO Panel Nod to Study Recombinant Human Follicle Stimulating Hormone

Image
New Delhi: Intas Pharmaceuticals has got approval from the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) to conduct a Phase I clinical trial of the Recombinant Human Follicle Stimulating Hormone 300 IU Solution for Injection. However, this approval is subject to the condition that the firm should have tied up with an IVF center in case of an emergency. This came after the firm presented the protocol to conduct a Phase I clinical study of Recombinant Human Follicle Stimulating Hormone 300 IU Solution for Injection titled " An open label, Phase-I, balanced, randomized, two-treatment, two-period, two-sequence, single subcutaneous dose administration, crossover, bioequivalence study of r-h-FSH (recombinant human follicle stimulating hormone injection), solution for injection of Intas Pharmaceuticals Limited, India with Gonal-f, recombinant human follicle stimulating hormone (r-hFSH) follitropin alfa, solution for injection ...
Read more

ICMR invites proposals for Centre for Advanced Research under Extramural Research Program, Details

Image
New Delhi- Through a notice, the Indian Council of Medical Research (ICMR) has called for concept proposals for the Centre for Advanced Research (CAR), under the Extramural Research Program. The Last Date for concept proposal is November 21, 2024. Under its Extramural Research Programme, the Indian Council of Medical Research (ICMR) funds the Centre for Advanced Research (CAR) to promote advanced research by experienced research teams.   What the CAR is expected to do: Conducting decisive research that helps in solving an important healthcare problem by a research team. It can have single or multiple linked research projects with clear deliverables. It encourages in-depth research, to generate new knowledge and solutions for health problems in multiple aspects of causation, progression, management and prevention. Priority diseases or conditions: Research teams planning to undertake studies in finding solutions for prevention, screening, diagnosis, treatment or rehabilita...
Read more